

We performed a study to assess the efficacy of Tegaderm™ CHG dressing for reducing catheter-related infections” Righetti et al (2016).

Abstract:

INTRODUCTION: Catheter-related infections are an important clinical problem in maintenance hemodialysis patients. Catheter-related bloodstream infections have a negative effect on survival, hospitalization and cost of care. Tegaderm™ chlorhexidine gluconate (CHG) dressing may be useful to reduce catheter-related infection rates.

METHODS: We performed a study to assess the efficacy of Tegaderm™ CHG dressing for reducing catheter-related infections. We designed a prospective randomized cross-over study with a scheme of two treatments, Tegaderm™ CHG dressing versus standard dressing, and two periods of six months. Catheter-related infection rate was the primary outcome. We enrolled 59 prevalent hemodialysis patients.

ReTweet if useful... CHG IV dressing improves CLABSI rates in hemodialysis patients
[@ivteam #ivteam](http://ctt.ec/Ahz4T+)

Click To Tweet

RESULTS: Catheter-related infection rate per 1000 catheter days was reduced from 1.21 in patients using standard dressing to 0.28 in patients with Tegaderm™ CHG dressing ($p = 0.02$). Catheter-related bloodstream infection rate per 1000 catheter days was equal to 0.09 in patients with Tegaderm™ CHG dressing versus 0.65 in patients with standard dressing ($p = 0.05$). Annual total healthcare costs for catheter-related bloodstream infections were estimated equal to EUR62,459 versus EUR300,399, respectively, for patients with Tegaderm™ CHG versus standard dressing.

CONCLUSIONS: This is the first prospective study to show that Tegaderm™ CHG dressing significantly reduces catheter-related infection rates in hemodialysis patients.

Reference:

Righetti, M., Palmieri, N., Bracchi, O., Prencipe, M., Bruschetta, E., Colombo, F., Brenna, I., Stefani, F1, Amar, K., Scalia, A. and Conte, F. (2016) Tegaderm™ CHG dressing



significantly improves catheter-related infection rate in hemodialysis patients. The Journal of Vascular Access. August 1st. .

doi: 10.5301/jva.5000596.

Thank you to our partners for supporting IVTEAM